PMID- 31950385
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20201119
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 180
IP  - 1
DP  - 2020 Feb
TI  - MRPS23 amplification and gene expression in breast cancer; association with 
      proliferation and the non-basal subtypes.
PG  - 73-86
LID - 10.1007/s10549-020-05532-6 [doi]
AB  - PURPOSE: MRPS23 is recognized as a driver of proliferation in luminal breast 
      cancer. The aims of the present study were to describe MRPS23 copy number change 
      in breast cancer, and to assess associations between MRPS23 copy number change 
      and molecular subtype, proliferation and prognosis, and between MRPS23 gene 
      expression and molecular subtype and prognosis. METHODS: Using fluorescence in 
      situ hybridization (FISH), we examined MRPS23 and centromere 17 copy number in 
      590 formalin-fixed, paraffin-embedded primary tumours and 144 corresponding lymph 
      node metastases from a cohort of Norwegian breast cancer patients. Furthermore, 
      we analysed MRPS23 gene expression data in 1971 primary breast cancer tumours 
      from the METABRIC dataset. We used Pearson's chi(2) test to assess associations 
      between MRPS23 copy number and molecular subtype and proliferation, and between 
      MRPS23 expression and molecular subtype. We studied prognosis by estimating 
      hazard ratios and cumulative incidence of death from breast cancer according to 
      MRPS23 copy number and MRPS23 expression status. RESULTS: We found MRPS23 
      amplification (mean MRPS23 copy number >/= 6 and/or MRPS23/chromosome 17 ratio >/= 2) 
      in 8% of primary tumours. Copy number increase associated with non-basal subtypes 
      and higher tumour cell proliferation (Ki67). Higher MRPS23 expression associated 
      with the Luminal B subtype. We found no significant association between MRPS23 
      amplification or MRSP23 gene expression, and prognosis. CONCLUSION: Amplification 
      of MRPS23 is associated with higher proliferation and non-basal subtypes in 
      breast cancer. High MRPS23 expression is associated with the Luminal B subtype.
FAU - Klaestad, Elise
AU  - Klaestad E
AUID- ORCID: 0000-0002-6635-8086
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology, Erling Skjalgssons 
      gate, 7030, Trondheim, Norway. elisekl@stud.ntnu.no.
FAU - Opdahl, Signe
AU  - Opdahl S
AD  - Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, 
      Norwegian University of Science and Technology, Trondheim, Norway.
FAU - Engstrom, Monica Jernberg
AU  - Engstrom MJ
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology, Erling Skjalgssons 
      gate, 7030, Trondheim, Norway.
AD  - Department of Breast and Endocrine Surgery, St. Olav's Hospital, Trondheim 
      University Hospital, 7006, Trondheim, Norway.
FAU - Ytterhus, Borgny
AU  - Ytterhus B
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology, Erling Skjalgssons 
      gate, 7030, Trondheim, Norway.
FAU - Wik, Elisabeth
AU  - Wik E
AD  - Department of Clinical Medicine, Section for Pathology, Centre for Cancer 
      Biomarkers CCBIO, University of Bergen, 5021, Bergen, Norway.
AD  - Department of Pathology, Haukeland University Hospital, 5021, Bergen, Norway.
FAU - Bofin, Anna Mary
AU  - Bofin AM
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology, Erling Skjalgssons 
      gate, 7030, Trondheim, Norway.
FAU - Valla, Marit
AU  - Valla M
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, Norwegian University of Science and Technology, Erling Skjalgssons 
      gate, 7030, Trondheim, Norway.
AD  - Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, 
      7006, Trondheim, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200116
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (RPS23 protein, human)
RN  - 0 (Ribosomal Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Cell Proliferation
MH  - DNA Copy Number Variations
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Middle Aged
MH  - Mitochondrial Proteins/*genetics
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Registries
MH  - Ribosomal Proteins/*genetics
PMC - PMC7031208
OTO - NOTNLM
OT  - Amplification
OT  - Breast cancer
OT  - Copy number
OT  - METABRIC
OT  - MRPS23
OT  - Proliferation
COIS- All authors declare that they have no conflicts of interest.
EDAT- 2020/01/18 06:00
MHDA- 2020/10/28 06:00
PMCR- 2020/01/16
CRDT- 2020/01/18 06:00
PHST- 2019/07/27 00:00 [received]
PHST- 2020/01/09 00:00 [accepted]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2020/01/16 00:00 [pmc-release]
AID - 10.1007/s10549-020-05532-6 [pii]
AID - 5532 [pii]
AID - 10.1007/s10549-020-05532-6 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Feb;180(1):73-86. doi: 10.1007/s10549-020-05532-6. 
      Epub 2020 Jan 16.